Skip to ContentSkip to Navigation
University of Groningenfounded in 1614  -  top 100 university
About us Practical matters How to find us dr. T.J.N. Hiltermann
University Medical Center Groningen

dr. T.J.N. Hiltermann

No picture available
E-mail:
t.j.n.hiltermann umcg.nl

Publications

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

Cell-Free DNA Based Next-Generation Sequencing Does Not Differentiate Between Oligoprogression and Systemic Progression in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors-An Explorative Study

Changes in global quality of life after treatment with immune checkpoint inhibitors in patients receiving different treatment regimens for advanced stage lung cancer in the Netherlands: a 2015-2021 cohort study

Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model

Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib

CT-assessed sarcopenia and immune-related adverse events in patients with lung cancer: A competing risk time-to-event analysis

Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement

Impact of CMV Infection and Cancer Treatment on Vaccine Efficacy in Oncology Patients

Longziekten

Press/media

Neo- en perioperatieve chemo-immunotherapie bij NSCLC

TLCR Outstanding Author interview

Rilvegostomig Elicits Responses in CPI-Naive NSCLC, Irrespective of PD-L1 TPS Status

Terminaal zieke John Franke strijdt met podcast voor bevolkingsonderzoek naar longkanker

Primeur met TCR T-cellen

EERSTE LONGKANKERPATIËNT BEHANDELD MET GEMODIFICEERDE T-CELLEN Primeur met TCR T-cellen